Canopy Growth Files Restated 10-K, Discloses Material Weakness, Management Cease Trade Order, and Major Investment Default
CGC sits 20% above its 52-week low of $0.844.
Summary
Canopy Growth filed its restated 10-K, revealing a material weakness in internal controls, a management cease trade order, and a default by its major U.S. investment, Acreage Holdings. The company also incurred significant dilution from recent capital raises and acquisitions.
Key Events · Corporate Governance and Compliance · CGC
-
Financial Restatement and Material Weakness
The company restated financial statements for fiscal years 2024, 2025, and 2026 due to accounting errors for share-settled warrants, leading to the identification of a material weakness in internal control over financial reporting as of March 31, 2026.
-
Management Cease Trade Order Issued
On May 28, 2026, the Ontario Securities Commission issued a management cease trade order against the CEO and CFO, prohibiting them from trading company securities due to the accounting errors, which may be lifted after this 10-K filing.
-
Acreage Holdings Defaults on Debt
Acreage Holdings, a key U.S. investment, is in default under its credit agreement. Canopy Growth's US$125.8 million investment in Acreage and Wana Debt is subordinate to another lender, posing a significant risk of loss.
-
Significant Dilution from ATM Programs and Acquisitions
During fiscal year 2026, Canopy Growth issued approximately 239.2 million shares through ATM programs and acquisitions, representing over 56% of its current outstanding shares. An additional US$102.0 million remains available under the August 2025 ATM program.
Analysis · CGC · Life Sciences
Canopy Growth has filed its annual 10-K, confirming the restatement of financial statements for fiscal years 2024, 2025, and 2026 due to accounting errors related to share-settled warrants. This restatement led to the identification of a material weakness in internal controls and a management cease trade order against the CEO and CFO. Furthermore, the company's significant investment in Acreage Holdings is at risk, as Acreage is in default under its credit agreement, potentially leading to a loss of Canopy Growth's US$125.8 million investment. While the company secured a new US$150 million loan, it came with substantial dilution through warrants and restrictions on its U.S. strategy. The company also issued a highly dilutive 239.2 million shares through ATM programs and acquisitions in the past fiscal year, representing over 56% of its current outstanding shares. These events collectively highlight significant financial, operational, and governance challenges, despite a reduction in net loss.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 42.7% of the 288 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.53%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CGC was trading at $1.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $452.1M. The 52-week trading range was $0.84 to $2.38. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.